Type 1 Diabetes

Clarivate’s “Drugs to Watch” list for 2023 mentions 15 therapeutics, including teplizumab for type 1 diabetes (T1D).

Individuals with a direct relative with type 1 diabetes (T1D) were 46 times more likely to have T1D and 17% more likely to have major depression, compared with individuals without.

This year’s most-read type 1 diabetes (T1D) articles highlighted important trends, breakthrough technologies, and more major findings for patients with T1D.

Tom Robinson, vice president of global access at JDRF, talks about how the community and people living with type 1 diabetes (T1D) have contributed to the T1D Index, from development to publication and going forward.

The study also showed daily energy intake was inversely correlated with estimated glucose disposal rate (eGDR), a marker for insulin resistance (IR).

Tom Robinson, vice president of global access at JDRF, lists 3 pieces of advice for groups looking to create indexes for other conditions similar to the Type 1 Diabetes (T1D) Index.

Due to the study’s small sample, further research is needed to understand the role of bromocriptine in reducing blood pressure and artery stiffness in youth with type 1 diabetes (T1D).

The first priority isn't limiting the rise in type 1 diabetes (T1D) prevalence, it's limiting the rise of missing prevalence, said Tom Robinson, vice president of global access at JDRF.

A review including nearly 40 million total participants showed a statistically significant positive association between infection with COVID-19 and risk of type 1 or type 2 diabetes.

Updating the Type 1 Diabetes (T1D) Index each year with the latest data and literature and implementing feedback is important for at least the first few years, said Tom Robinson, vice president of global access at JDRF.

Serum bicarbonate level also did not appear to affect the accuracy of real-time continuous glucose monitoring (rtCGM) in pediatric diabetic ketoacidosis (DKA).

Get type 1 diabetes (T1D) communities involved in solving the problem and implementing T1D interventions in your country, said Tom Robinson, vice president of global access at JDRF.

The biologic is the first drug that aims to delay the diagnosis of type 1 diabetes.

The 10-year follow-up in the DIACAM 1 study demonstrated a notable increase in prevalence of different types of autoimmune diseases among patients with type 1 diabetes (T1D).

While each country has a different priority when it comes to type 1 diabetes (T1D) diagnosis and treatment, there is a fairly consistent outcomes checklist across nations, said Tom Robinson, vice president of global access at JDRF.

An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitor use in people with type 1 diabetes.

Tom Robinson, vice president of global access at JDRF, talks about the data collection process in creating the Type 1 Diabetes (T1D) Index.

Considerable research on diabetic ketoacidosis (DKA) risk has been published since the publication of a 2011 systematic review, warranting an updated analysis.

Tom Robinson, vice president of global access at JDRF, talks about the predictive modeling exercise used to develop and refine the Type 1 Diabetes (T1D) Index.

Serum α-synuclein was found to be increased in children with obesity and type 1 diabetes (T1D), which was linked to the impairment of executive function in these children.

According to Tom Robinson, vice president of global access at JDRF, the creation of the Type 1 Diabetes (T1D) Index was prompted by a lack of basic data on the condition, such as how many people are living with and affected by T1D.

People with diabetes in Italy and the United Kingdom reported the highest rates of anxiety at 63% and 51%, respectively.

Tom Robinson, vice president of global access at JDRF, explains how to navigate the Type 1 Diabetes (T1D) Index and what data can be pulled from it.

The bionic pancreas uses algorithms to continually adjust insulin doses based on the user’s needs, requiring less user input compared with other existing artificial pancreas technologies.

The Type 1 Diabetes (T1D) Index measures global T1D prevalence and provides other statistics and estimates related to the autoimmune condition.

In 2040, researchers predict between 13.5 and 17.4 million type 1 diabetes (T1D) cases globally, reflecting a 60% to 107% increase in cases compared with 2021.

A deal was reached to renew 5-year FDA user fee programs; children and adolescents with COVID-19 had a 60% increased risk of developing type 1 diabetes (T1D); states cannot penalize Department of Veterans Affairs (VA) employees for facilitating abortions permitted by federal law.

Children and adolescents with type 1 diabetes (T1D) saw improved quality of life (QOL) and metabolic control when using an advanced hybrid closed-loop (AHCL) insulin delivery method vs conventional therapy.

Treating children with mild diabetic ketoacidosis (DKA) using subcutaneous (SC) insulin aspart was linked to lower hospital costs and better efficacy of DKA management, compared with using intravenous (IV) insulin.

Women with type 1 diabetes (T1D) had a better cardiometabolic risk factor profile but did not have a significantly lower cardiovascular disease (CVD) event burden compared with their male counterparts.